Hemostemix Inc.
HEM
Rangering i aksjer
#32557
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
Aksjekurs
$0.04268108
Sist synkronisert: 2026-10-21
Markedsverdi
$9.02M
Endring (1 dag)
5.73%
Endring (1 år)
-42.09%
Land
CA
Handel Hemostemix Inc. (HEM)
Kategori
Healthcare
Aksjeprishistorikk for Hemostemix Inc. (HEM)
Høyeste sluttskurs: $0.04 den 2026-10-01
Laveste sluttskurs: $0.00 den 2005-11-01
Laveste sluttskurs: $0.00 den 2005-11-01
Aksjeprishistorikk for Hemostemix Inc. fra 2005 til 2026
Årlig aksjeprisytelse
| År | Ytelse |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
Aksjepris for lignende selskaper eller konkurrenter
| Selskap | Aksjepris | Endring 1år% | Land |
|---|---|---|---|
| $533.96 | 25.21% |
US
|
|
| $232.80 | 767.04% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $882.27 | 8.36% |
NL
|
|
| $290.30 | 1.99% |
BE
|
